초록 ▼

The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoprotein

The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.

대표청구항 ▼

1. A method for purifying lipoproteins suitable for differential charged-particle mobility analysis of lipoprotein class and subclass, said method comprising: (a) preparing a centrifuge tube containing a first solution underneath a sample and a second solution above said sample, said sample comprisi

1. A method for purifying lipoproteins suitable for differential charged-particle mobility analysis of lipoprotein class and subclass, said method comprising: (a) preparing a centrifuge tube containing a first solution underneath a sample and a second solution above said sample, said sample comprising high density lipoproteins (HDL) and non-lipoprotein components, said first solution having a first density greater than 1.00 g/mL and less than or equal to about 1.21 g/mL, and said second solution having a second density greater than or equal to 1.00 g/mL and less than said first density;(b) subjecting said tube to centrifugation sufficient to cause said non-lipoprotein components to migrate toward the bottom of the tube and away from said lipoproteins, thereby providing purified lipoproteins;wherein said sample further comprises dextran sulfate under conditions wherein said HDL are not precipitated from said sample. 2. The method according to claim 1, wherein said first density is in the range of about 1.15 g/mL to about 1.21 g/mL. 3. The method according to claim 1, wherein said HDL and non-lipoprotein components are from a plasma sample. 4. The method according to claim 1, wherein said centrifugation does not reach equilibrium. 5. The method according to claim 1, further comprising: (c) collecting said purified lipoproteins from the top portion of said centrifuge tube following centrifugation. 6. The method according to claim 5, wherein Lp(a) is removed from said collected lipoproteins by: (a) forming a precipitate comprising Lp(a) by admixing said collected lipoproteins with a precipitant for Apo B-containing lipoprotein under conditions sufficient to cause precipitation of Lp(a); and(b) isolating said Lp(a) containing precipitate from the collected lipoproteins. 7. The method according to claim 1, wherein said sample further comprises an albumin-binding compound capable of binding albumin to form an albumin-albumin binding compound complex, andwherein said centrifugation causes said albumin-albumin binding compound complex to be separated from said purified lipoproteins. 8. The method according to claim 7, wherein said albumin-binding compound is an analog of nicotinamide adenine dinucleotide (NAD). 9. The method according to claim 8, wherein said NAD analog is selected from the group consisting of Reactive Green 19 and Cibacrom Blue 3GA. 10. The method according to claim 8, wherein said NAD analog is conjugated to a chromatographic medium selected from the group consisting of paramagnetic particles, dextran, and agarose. 11. The method according to claim 1, wherein said sample further comprises a non-lipoprotein capture ligand capable of binding non-lipoprotein to form a non-lipoprotein/non-lipoprotein capture ligand complex, andwherein said centrifugation causes said non-lipoprotein/non-lipoprotein capture ligand complex to be separated from said lipoprotein components. 12. The method according to claim 11, wherein said non-lipoprotein capture ligand is selected from the group consisting of aptamer and antibody. 13. The method according to claim 1, wherein Lp(a) is removed from said sample prior to centrifugation by: (a) forming a precipitate of Lp(a) by admixing said sample with a precipitant for Apo B-containing lipoprotein under conditions sufficient to cause precipitation of Lp(a); and(b) isolating said Lp(a) containing precipitate from said sample. 14. The method according to claim 13, wherein said precipitant for Apo B-containing lipoprotein comprises dextran sulfate and a divalent cation. 15. The method according to claim 14, wherein said divalent cation is Mg2+. 16. The method according to claim 1, wherein said first solution comprises deuterium oxide. 17. The method according to claim 16, wherein said first solution comprises a solvent that is substantially deuterium oxide. 18. The method according to claim 1, wherein said first solution is in contact with an inert centrifugation matrix. 19. The method according to claim 18, wherein said inert centrifugation matrix comprises gel slurry or inert beads. 20. The method according to claim 19, wherein said gel slurry comprises a gel matrix. 21. The method according to claim 19, wherein said inert centrifugation matrix comprises inert beads. 22. The method according to claim 1, wherein said sample further comprises one or more lipoproteins selected from the group consisting of intermediate density lipoproteins (IDL), very low density lipoproteins (VLDL), and lipoprotein (a) (Lp(a)). 23. The method according to claim 22, wherein said sample further comprises low density lipoproteins (LDL). 24. The method according to claim 23, wherein said sample further comprises three or more of IDL, VLDL, Lp(a), and LDL. 25. A method for purifying lipoproteins, said method comprising: (a) preparing a centrifuge tube containing a sample and a first solution located below and adjacent to said sample, said sample comprising one or more lipoproteins and non-lipoprotein components,said sample further comprising Reactive Green dextran and dextran sulfate,said first solution comprising deuterium oxide; and(b) subjecting said tube to centrifugation sufficient to cause said non-lipoprotein components to migrate toward the bottom of the tube and away from said lipoproteins. 26. The method according to claim 25, wherein said first solution has a density in the range 1.00 g/mL to about 1.21 g/mL. 27. The method according to claim 25, wherein said first solution has a density in the range 1.00 g/mL to about 1.10 g/mL.